RxDoctor Payments DataLook up a doctor →

Rajkumar Sugumaran, MD

Cardiovascular Disease · Phoenix, AZNPI 1184840506

Payments from drug & device makers

$957,253in general payments, 2019–2025

Across 1,739 payments — averaging $550.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$319K
  • Boehringer Ingelheim$160K
  • Lilly USA, LLC$138K
  • Novo Nordisk$120K
  • Novartis$64K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$47K
  • plus $109K from 48 others
$2,796in research payments, 2019–2025

Across 2 payments — averaging $1397.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$957,253 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$529,860
Medicare patients
857
Services billed
5,459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →